20 June, 2017
(NASDAQ:GILD). Swedbank invested in 1.47% or 2.60 million shares. It is down 0.00% since June 20, 2016 and is. It has outperformed by 44.52% the S&P500. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $88.85.
Semper Augustus Investments Group Llc increased its stake in Goldcorp Inc New (GG) by 18.68% based on its latest 2016Q4 regulatory filing with the SEC. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company's stock valued at $112,000 after buying an additional 144 shares during the period. Insiders have sold a total of 88,276 shares of company stock valued at $5,932,578 over the last 90 days. Gilead Sciences, Inc. The company has a market cap of $84.70 billion, a price-to-earnings ratio of 6.85 and a beta of 1.20. The stock decreased 1.06% or $0.69 during the last trading session, reaching $64.12. Lombard Odier Asset Management Usa Corp bought 244,904 shares as the company's stock declined 4.26% while stock markets rallied.
Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, May 2nd. It has underperformed by 38.50% the S&P500. Investors of record on Friday, June 16th will be given a dividend of $0.52 per share. Its down 0.23, from 0.93 in 2016Q3.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of GILD. The biopharmaceutical company reported $2.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.18 by $0.02. It also upped Vanguard (VWO) stake by 66,610 shares and now owns 94,596 shares. (NASDAQ:GILD) has been on a free fall - declining -7.15 percent in just three months. The stock is now trading -13.06% below its SMA 50 and -30.64% below its SMA 200. Boston Common Asset Limited Liability Corp holds 0.93% or 89,197 shares in its portfolio. (NASDAQ:GILD) by 46.7% during the first quarter, according to its most recent Form 13F filing with the SEC. Neville Rodie & Shaw Inc stated it has 0.64% in Gilead Sciences, Inc. The firm earned "Buy" rating on Friday, February 12 by Maxim Group. (NASDAQ:GILD) for 18,725 shares. (NASDAQ:GILD) was sold by MARTIN JOHN C on Wednesday, February 1. 252,584 are owned by Delta Lloyd Nv.
ILLEGAL ACTIVITY WARNING: "Trust Department MB Financial Bank N A Cuts Position in Gilead Sciences, Inc". Gilead Sciences had a net margin of 43.42% and a return on equity of 76.64%. (NASDAQ:GILD) for 389 shares. Meridian Investment Counsel accumulated 0.47% or 9,771 shares. On the other side, analysts now consider Gilead Sciences, Inc. a neutral, and a technical analysis of the stock is setting somewhat neutral outlook for now.
Since January 3, 2017, it had 0 buys, and 11 selling transactions for $33.68 million activity. (NASDAQ:GILD) shares were sold by WILSON GAYLE E. Also, EVP Gregg H. Alton sold 5,000 shares of the stock in a transaction dated Thursday, March 30th. Another trade for 9,943 shares valued at $668,667 was made by Cogan John Francis on Tuesday, May 9. Goldman Sachs Group, Inc. Capwealth Advsrs Ltd Liability Company invested in 2.13% or 137,730 shares. GILD's profit will be $2.75B for 7.60 P/E if the $2.13 EPS becomes a reality. About shares traded. Gilead Sciences, Inc. Therefore 100% are positive. William Blair reiterated an "outperform" rating on shares of Gilead Sciences in a report on Friday. Leerink Swann has "Mkt Perform" rating and $94 target. The firm earned "Outperform" rating on Wednesday, February 3 by Oppenheimer. (NASDAQ:GILD) on Wednesday, July 29 with "Buy" rating. Hall Laurie J Trustee increased its position in shares of Gilead Sciences by 20.0% in the first quarter. The stock has "Hold" rating by Needham on Tuesday, July 26. As per Monday, September 21, the company rating was maintained by Cowen & Co. Winfield Associate owns 1,080 shares for 0.05% of their portfolio. Finally, State Street Corp increased its position in Gilead Sciences by 4.5% in the fourth quarter. (NYSE:NSC) by 34,749 shares in the quarter, for a total of 44,659 shares, and has risen its stake in Intercontinentalexchange Group (NYSE:ICE). Five analysts have issued estimates for Gilead Sciences' earnings, with the lowest EPS estimate coming in at $1.87 and the highest estimate coming in at $2.17. The stock of Gilead Sciences, Inc. Atlantic Securities has "Neutral" rating and $111 target. Therefore 53% are positive. Torstar Corporation had 9 analyst reports since July 28, 2015 according to SRatingsIntel. The stock has "Hold" rating by Jefferies on Wednesday, August 31. The company was upgraded on Monday, October 3 by Deutsche Bank. On Thursday, February 25 the stock rating was initiated by Citigroup with "Buy". The rating was maintained by RBC Capital Markets on Wednesday, November 2 with "Outperform". The rating was maintained by Jefferies with "Hold" on Tuesday, March 15. It is 0.00% or $0 reaching $1.55 per share. Its down 0.23, from 0.93 in 2016Q3. Investors will be waiting to see if shares see a turnaround in the next few weeks. Notis holds 0.7% or 14,247 shares. Natl Bank reported 68,690 shares stake. Pacwest stated it has 10,115 shares or 0.43% of all its holdings. 108,882 were reported by Clinton Grp Inc. Bahl Gaynor holds 24,530 shares. Aviance Capital Partners Ltd Liability Corp reported 15,719 shares. Fort Washington Inv Inc Oh reported 0.21% stake. (NASDAQ:GILD). Westfield Capital Mngmt Company L P, a Massachusetts-based fund reported 1.40M shares. ADR NQ (US: NYSE)" on April 29, 2011, also Marketwatch.com with their article: "3.42" published on May 06, 2011, Valuewalk.com published: "NQ Mobile All Over Again? Naples Global Advisors Llc, a Florida-based fund reported 13,233 shares. Jpmorgan Chase & invested 0% in Griffon Corporation (NYSE:GFF). Argent Mngmt Lc accumulated 0.02% or 14,630 shares.
